TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

TQB2930 is a HER2 bispecific antibody drug. This study aims to evaluate the efficacy and safety of TQB2930 combined with investigator's choice of chemotherapy versus trastuzumab combined with investigator's choice of chemotherapy in subjects with HER2-positive advanced breast cancer who have received at least two prior lines of anti-HER2 therapy in the advanced station.

Trial Details

NCT ID
NCT07047365
Phase
PHASE3
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • TQB2930+ chemotherapy
  • Trastuzumab+ chemotherapy
Locations (sample)
  • Bengbu, Anhui, China|32.94083,117.36083
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Lanzhou, Gansu, China|36.05701,103.83987
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Subjects voluntarily participate in this study and sign the informed consent form;
  • Age: 18-75 years (at time of signing Informed Consent Form (ICF); Eastern Cooperative Oncology Group (ECOG) performance status ≤1; estimated life e…
  • Cytologically or histologically confirmed Human Epidermal Growth Factor Receptor 2 (HER2)-positive recurrent or metastatic breast cancer;
  • Received ≥2 prior lines of anti-HER2 targeted therapy in the advanced setting;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →